Skip to content
Triangle logo TriangleGet started
← Study library

NCT03075553 · REGISTRY CONDITION SEARCH

Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE2
Status at capture
TERMINATED
Registry last update
2020-04-21

This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Response Rate for Participants Who Achieve a CR or PR [CT-based Response]

→

outcome · POSTED

Response Rate for Participants Who Achieve a CMR or PMR [PET-CT-based Response]

→

outcome · POSTED

Duration of Response (DOR)

→

outcome · POSTED

Progression-Free Survival (PFS)

→

outcome · POSTED

Overall Survival (OS)

→

outcome · POSTED

Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
Inclusion Criteria: * Relapsed or refractory T-cell lymphoma (TCL) biopsy-proven =\< 6 months prior to registration, including the following subtypes: * Peripheral T-cell lymphoma, not otherwise specified * Anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK) negative, primary systemic type * Angioimmunoblastic T-cell lymphoma * Extranodal natural killer (NK)/T-cell lymphoma, nasal type * Adult T-cell lymphoma/leukemia (human T-lymphotropic virus 1 \[HTLV1\]+) * Blastic NK-cell lymphoma * Enteropathy-associated T-cell lymphoma * Hepatosplenic gamma delta T-cell lymphoma * Transformed mycosis fungoides * T/NK-cell lymphoma, unclassifiable * Measurable disease: subjects must have at least one lesion that is \> 15mm (1.5 cm) in the longest diameter on cross-sectional imaging and measureable in two perpendicular dimensions per computed tomography (spiral CT) or magnetic resonance imaging (MRI) * After failure of allogeneic stem cell transplant (ASCT) or after failure of frontline therapy in subjects who declined or are not ASCT candidates * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * White blood cell (WBC) \>= 3000/mm\^3 * Absolute neutrophil count (ANC) \>= 1500/mm\^3 * Platelet count \>= 100,000/mm\^3 * Hemoglobin \> 9.0 g/dL * Total bilirubin =\< 1.5 x upper limit of normal (ULN) unless elevation due to Gilbert's Syndrome * Aspartate transaminase (AST) =\< 2.5 x ULN * Creatinine =\< 2.0 mg/dL * Calculated creatinine clearance must be \>= 45 ml/min using the Cockcroft-Gault formula * Negative serum or urine pregnancy test done =\< 7 days prior to registration, for persons of childbearing potential only Note: Persons of child-bearing potential (POCBP) must use appropriate method(s) of contraception; POCBP should use an adequate method to avoid pregnancy for 23 weeks (30 days plus the time required for nivolumab to undergo five half-lives) after the last dose of investigational drug; men who are sexually active with POCBP must use any contraceptive method with a failure rate of less than 1% per year; men receiving nivolumab and who are sexually active with POCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; persons who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraception; should a person become pregnant or suspect being pregnant while participating in this study, the person should inform the treating physician immediately * Provide written informed consent * Willing to return to enrolling institution for follow-up during the Active Monitoring phase of the study * Willing to provide tissue and blood samples for correlative research purposes Exclusion Criteria: * All primary cutaneous T-cell lymphomas * Any of the following: * Pregnant women * Nursing women * Men or women of childbearing potential who are unwilling to employ adequate contraception * Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens * Active, known or suspected autoimmune disease Note: subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment * Use of systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications \< 14 days of registration Note: inhaled or topical steroids are permitted; \> 10 mg daily prednisone equivalents are permitted only in adrenal insufficiency in the absence of active autoimmune disease * Prohibited treatments and or therapies * Autologous stem cell transplant (ASCT) =\< 12 weeks prior to first dose of the study drug * Prior treatments (window prior to registration): * Chemotherapy =\< 2 weeks * Nitrosureas =\< 6 weeks * Therapeutic anticancer antibodies =\< 4 weeks * Radio- or toxin immunoconjugates =\< 10 weeks * Radiation therapy =\< 3 weeks * Or major surgery =\< 2 weeks * Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways * Prior allogeneic stem cell transplant (SCT) * Chest radiation =\< 24 weeks prior to registration * Immunocompromised patients, patients with known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) and currently receiving antiretroviral therapy, active hepatitis B virus surface antigen (HBV sAg+), active hepatitis C (if Ab+ then PCR+) indicating acute or chronic infection * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements * Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm * Other active malignancy =\< 3 years prior to registration EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix NOTE: if there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer * Active central nervous system (CNS) involvement or leptomeningeal involvement * History of pancreatitis
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Patients receive nivolumab IV over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity.
    intervention Names
    1. Other: Laboratory Biomarker Analysis
    2. Biological: Nivolumab
    label
    Treatment (nivolumab)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (nivolumab)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  2. arm Group Labels
    1. Treatment (nivolumab)
    description
    Given IV
    name
    Nivolumab
    other Names
    1. BMS-936558
    2. MDX-1106
    3. NIVO
    4. ONO-4538
    5. Opdivo
    type
    BIOLOGICAL
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
12
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    The response rate for participants who achieve a CR or PR is defined as the percentage of participants who achieve a CR or PR assessed according to the revised Lugano Classification Response criteria. Complete response (CR): target nodes/nodal masses must regress to \<=1.5 cm in longest transverse diameter (LDi). Partial response (PR): \>= 50% decrease in sum of the product of the diameters (SPD) of up to 6 target measurable nodes and extranodal sites.
    measure
    Response Rate for Participants Who Achieve a CR or PR [CT-based Response]
    time Frame
    Up to 390 days
secondary Outcomes
  1. description
    The response rate for participants who achieve a CMR or PMR is defined as the percentage of participants who achieve a CMR or PMR assessed according to the revised Lugano Classification Response criteria. Complete metabolic response (CMR): Score 1, 2, or 3 with/without a residual mass using the Lugano 5-Point Scale (5-PS). Partial metabolic response (PMR): Score 4 or 5 with reduced update from baseline. The Lugano 5-PS is a scale used for initial staging and assessment of treatment response in Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphomas (NHL). The scale ranges from 1 to 5, where 1 is best and 5 is the worst. Each FDG-avid (or previously FDG-avid) lesion is rated independently: 1. no uptake or no residual uptake 2. slight uptake, but equal to or below blood pool 3. uptake above mediastinal, but below or equal to uptake in the liver 4. uptake slightly to moderately higher than liver 5. markedly increased uptake or any new lesion (on response evaluation)
    measure
    Response Rate for Participants Who Achieve a CMR or PMR [PET-CT-based Response]
    time Frame
    Up to 390 days
  2. description
    The distribution of duration of response (CR or PR) will be estimated using the method of Kaplan-Meier. Complete response (CR): target nodes/nodal masses must regress to \<=1.5 cm in longest transverse diameter (LDi). Partial response (PR): \>= 50% decrease in sum of the product of the diameters (SPD) of up to 6 target measurable nodes and extranodal sites.
    measure
    Duration of Response (DOR)
    time Frame
    Up to 390 days
  3. description
    The distribution of progression-free survival will be estimated using the method of Kaplan-Meier. In addition, the progression-free survival rate will be reported. progressive disease (PD): a Lugano score of 4 to 5 with increasing intensity compared to baseline or any interim scan and/or any new FDG-avid focus consistent with malignant lymphoma.The Lugano 5-PS is a scale used for initial staging and assessment of treatment response in Hodgkin lymphoma (HL) and certain types of non-Hodgkin lymphomas (NHL). The scale ranges from 1 to 5, where 1 is best and 5 is the worst. Each FDG-avid (or previously FDG-avid) lesion is rated independently: 1. no uptake or no residual uptake 2. slight uptake, but equal to or below blood pool 3. uptake above mediastinal, but below or equal to uptake in the liver 4. uptake slightly to moderately higher than liver 5. markedly increased uptake or any new lesion (on response evaluation)
    measure
    Progression-Free Survival (PFS)
    time Frame
    The time from registration to relapse or death due to any cause, an average of 2 years
  4. description
    The distribution of survival time will be estimated using the method of Kaplan-Meier.
    measure
    Overall Survival (OS)
    time Frame
    The time from registration to death due to any cause, assessed up to 2 years
  5. description
    The number of participants who experienced at least one grade 3 or higher adverse events are summarized below.
    measure
    Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Events
    time Frame
    Up to 390 days
Full study description
brief Summary
This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.
detailed Description
PRIMARY OBJECTIVES: I. To assess the clinical benefit of nivolumab in T-cell lymphomas, as measured by objective response rate (ORR) within 12 cycles according to the Lugano Classification Response Criteria (2014). SECONDARY OBJECTIVES: I. To assess safety and tolerability of the regimen in this patient population. II. To assess progression-free survival (PFS). III. To assess duration of response (DOR). IV. To assess overall survival (OS). TERTIARY OBJECTIVES: I. To evaluate T-cell/cytokine profile in the peripheral blood - peripheral blood specimens will be used to assess T-cell activation and cytokine up regulation as measures of treatment effect. II. To evaluate intratumoral biomarkers- intratumoral cell populations and distribution, genetic variability, mutational burden and T-cell activation will be evaluated to identify potential biomarkers that correlate with response to therapy. III. To assess the potential association between PD-L1/PD-1/PD-L2 expression on tumor and T-cells and/or PD-L1 soluble levels in plasma with clinical efficacy of PD-1 blockade. OUTLINE: Patients receive nivolumab intravenously (IV) over 60 minutes on day 1. Treatment repeats every 14 days for up to 8 courses in the absence of disease progression or unacceptable toxicity. Patients achieving stable disease, complete response, or partial response receive nivolumab IV over 60 minutes on day 1 of course 9. Treatment repeats every 28 days for up to 24 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 35 days, 100-120 days, 230-250 days, and 330-390 days.
Source references
references
  1. citation
    Bennani NN, Kim HJ, Pederson LD, Atherton PJ, Micallef IN, Thanarajasingam G, Nowakowski GS, Witzig T, Feldman AL, Ansell SM. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression. J Immunother Cancer. 2022 Jun;10(6):e004984. doi: 10.1136/jitc-2022-004984.
    pmid
    35750419
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-5f36097d9e4e9cf0d562
      requested nct id
      NCT03075553
      primary nct id
      NCT03075553
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      payload sha256
      edbeedf89c81022063240d66788d70a2597139939a361c571415146866025022
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-5f36097d9e4e9cf0d562
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT03075553
      occurrences
      1. context exact
        NCT03075553
        end
        11
        exact text
        NCT03075553
        start
        0
      offset unit
      unicode_code_points
      query cond
      Peripheral T-Cell Non-Hodgkin Lymphoma
      query disease state id
      ds-peripheral-t-cell-non-hodgkin-lymphoma
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-peripheral-t-cell-non-hodgkin-lymphoma-000.json
      source file sha256
      e270600534699a676fe83226e7a7b0f73aeb00c1d0a05cfc115c748864ad8173
      source json pointer
      /studies/52/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      7ab46bb8a43eeca65db19eb99acc27908b4a86ce67abb921e70ff1453be5672d

    Preserved source evidence · Not medical advice